Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review
Marianne Chapleau, Leonardo Iaccarino, David N. Soleimani‐Meigooni, et al.
Journal of Nuclear Medicine (2022) Vol. 63, Iss. Supplement 1, pp. 13S-19S
Open Access | Times Cited: 107

Showing 1-25 of 107 citing articles:

Emerging diagnostics and therapeutics for Alzheimer disease
Wade Self, David M. Holtzman
Nature Medicine (2023) Vol. 29, Iss. 9, pp. 2187-2199
Closed Access | Times Cited: 184
Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update
Golnaz Yadollahikhales, Julio C. Rojas
Neurotherapeutics (2023) Vol. 20, Iss. 4, pp. 914-931
Open Access | Times Cited: 88
Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
Anne‐Cathrine S. Vogt, Gary T. Jennings, Mona O. Mohsen, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3895-3895
Open Access | Times Cited: 52
Phenomic Studies on Diseases: Potential and Challenges
Weihai Ying
Phenomics (2023) Vol. 3, Iss. 3, pp. 285-299
Open Access | Times Cited: 49
A novel ultrasensitive assay for plasma p‐tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease
Fernándo González‐Ortiz, Pâmela C.L. Ferreira, Armand González‐Escalante, et al.
Alzheimer s & Dementia (2023) Vol. 20, Iss. 2, pp. 1239-1249
Open Access | Times Cited: 44
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid
Matthew R. Meyer, Kristopher M. Kirmess, Stephanie Eastwood, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 5, pp. 3179-3192
Open Access | Times Cited: 39
Alzheimer’s disease and drug delivery across the blood–brain barrier: approaches and challenges
Iram Iqbal, Fatima Saqib, Zobia Mubarak, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 16
Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry
Andrew H. Miller, Michael Berk, Gilles Bloch, et al.
Brain Behavior and Immunity (2025) Vol. 125, pp. 319-329
Closed Access | Times Cited: 3
Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF Aβ42/Aβ40 ratios, neurofilament light and tau in Alzheimer’s disease model mice
Emelie Andersson, Nils JN Lindblom, Shorena Janelidze, et al.
Nature Aging (2025)
Open Access | Times Cited: 3
The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization
Amanda M. Leisgang Osse, Jefferson W. Kinney, Jeffrey L. Cummings
Alzheimer s & Dementia Translational Research & Clinical Interventions (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 2
Donanemab: Appropriate use recommendations
G D Rabinovici, D. J. Selkoe, Suzanne E. Schindler, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100150-100150
Open Access | Times Cited: 2
Differentiating Cerebral Amyloid Angiopathy From Alzheimer’s Disease Using Dual Amyloid and Tau Positron Emission Tomography
Hsin-Hsi Tsai, Marco Pasi, Chia‐Ju Liu, et al.
Journal of Stroke (2025) Vol. 27, Iss. 1, pp. 65-74
Open Access | Times Cited: 1
Is Australia ready for the rollout of amyloid‐targeting therapies for Alzheimer's disease? Results from a national survey characterising current infrastructure capability, workforce and training needs of memory and cognition clinics
Johannes C. Michaelian, Christopher C. Rowe, Susan Kurrle, et al.
Internal Medicine Journal (2025)
Open Access | Times Cited: 1
A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment
Mark Monane, Kim Johnson, B. Joy Snider, et al.
Annals of Clinical and Translational Neurology (2023) Vol. 10, Iss. 10, pp. 1738-1748
Open Access | Times Cited: 22
The therapeutic landscape of tauopathies: challenges and prospects
Jeffrey L. Cummings, María Isabel González, Martyn C. Pritchard, et al.
Alzheimer s Research & Therapy (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 22
Cell-type-specific Alzheimer’s disease polygenic risk scores are associated with distinct disease processes in Alzheimer’s disease
Hyun‐Sik Yang, Ling Teng, Daniel W. Kang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 21
SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T
Philipp E. Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 11, pp. 3465-3474
Open Access | Times Cited: 18
Fluorine-18-Labeled Diaryl-azines as Improved β-Amyloid Imaging Tracers: From Bench to First-in-Human Studies
Yuying Li, Kaixiang Zhou, Xiaojun Zhang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 4603-4616
Closed Access | Times Cited: 17
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
Pepijn Eijsvogel, Pinaki Misra, Luis Concha‐Marambio, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2631-2640
Open Access | Times Cited: 8
Targeting misfolding and aggregation of the amyloid-β peptide and mutant p53 protein using multifunctional molecules
Lauryn Grcic, Grace Leech, Kalvin Kwan, et al.
Chemical Communications (2024) Vol. 60, Iss. 11, pp. 1372-1388
Closed Access | Times Cited: 7
Novel avenues of tau research
Claire E. Sexton, Gal Bitan, Kathryn R. Bowles, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 3, pp. 2240-2261
Open Access | Times Cited: 7
Anti-amyloid Antibody Therapies for Alzheimer’s Disease
Kyung Won Park
Nuclear Medicine and Molecular Imaging (2024) Vol. 58, Iss. 4, pp. 227-236
Closed Access | Times Cited: 7
Integrating amyloid and tau imaging with proteomics and genomics in Alzheimer’s disease
Gabriele Vilkaite, Jacob W. Vogel, Niklas Mattsson
Cell Reports Medicine (2024) Vol. 5, Iss. 9, pp. 101735-101735
Open Access | Times Cited: 7
Prostate‐Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer
Niranjan Meher, Gary W. Ashley, Kondapa Naidu Bobba, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 19
Open Access | Times Cited: 6
[18F]Flotaza for Aβ Plaque Diagnostic Imaging: Evaluation in Postmortem Human Alzheimer’s Disease Brain Hippocampus and PET/CT Imaging in 5xFAD Transgenic Mice
Yasmin K. Sandhu, Harman S. Bath, Jasmine Shergill, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7890-7890
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top